112 related articles for article (PubMed ID: 38472095)
1. Evaluation of the cytotoxic activity of sorafenib-loaded camel milk casein nanoparticles against hepatocarcinoma cells.
Mittal A; Mahala N; Dhanawade NH; Dubey SK; Dubey US
Biotechnol J; 2024 Mar; 19(3):e2300449. PubMed ID: 38472095
[TBL] [Abstract][Full Text] [Related]
2. The Synergistic Cytotoxic Effect of Laser-Irradiated Gold Nanoparticles and Sorafenib Against the Growth of a Human Hepatocellular Carcinoma Cell Line.
Ebrahim HM; El-Rouby MN; Morsy ME; Said MM; Ezz MK
Asian Pac J Cancer Prev; 2019 Nov; 20(11):3369-3376. PubMed ID: 31759361
[TBL] [Abstract][Full Text] [Related]
3. Camel milk triggers apoptotic signaling pathways in human hepatoma HepG2 and breast cancer MCF7 cell lines through transcriptional mechanism.
Korashy HM; Maayah ZH; Abd-Allah AR; El-Kadi AO; Alhaider AA
J Biomed Biotechnol; 2012; 2012():593195. PubMed ID: 22654482
[TBL] [Abstract][Full Text] [Related]
4. Design And Characterisation Of Novel Sorafenib-Loaded Carbon Nanotubes With Distinct Tumour-Suppressive Activity In Hepatocellular Carcinoma.
Elsayed MM; Mostafa ME; Alaaeldin E; Sarhan HA; Shaykoon MS; Allam S; Ahmed AR; Elsadek BE
Int J Nanomedicine; 2019; 14():8445-8467. PubMed ID: 31754301
[TBL] [Abstract][Full Text] [Related]
5. PEGylated trimethylchitosan emulsomes conjugated to octreotide for targeted delivery of sorafenib to hepatocellular carcinoma cells of HepG2.
Varshosaz J; Raghami F; Rostami M; Jahanian A
J Liposome Res; 2019 Dec; 29(4):383-398. PubMed ID: 30668221
[TBL] [Abstract][Full Text] [Related]
6. Bovine Serum Albumin Nanoparticle-Mediated Delivery of Sorafenib for Improving Hepatocellular Carcinoma Therapy.
Ming Y; Li B; Fu R; Xing H; Liu Y; Duan D; Li Z; Li L; Ni R; Xu J; Li C; Xiang M; Song H; Chen J
J Nanosci Nanotechnol; 2021 Oct; 21(10):5075-5082. PubMed ID: 33875093
[TBL] [Abstract][Full Text] [Related]
7. Novel FLT3/AURK multikinase inhibitor is efficacious against sorafenib-refractory and sorafenib-resistant hepatocellular carcinoma.
Lai YL; Wang KH; Hsieh HP; Yen WC
J Biomed Sci; 2022 Jan; 29(1):5. PubMed ID: 35062934
[TBL] [Abstract][Full Text] [Related]
8. Anti-GPC3 antibody-modified sorafenib-loaded nanoparticles significantly inhibited HepG2 hepatocellular carcinoma.
Tang X; Chen L; Li A; Cai S; Zhang Y; Liu X; Jiang Z; Liu X; Liang Y; Ma D
Drug Deliv; 2018 Nov; 25(1):1484-1494. PubMed ID: 29916268
[TBL] [Abstract][Full Text] [Related]
9. Resistance of hepatocellular carcinoma to sorafenib can be overcome with co-delivery of PI3K/mTOR inhibitor BEZ235 and sorafenib in nanoparticles.
Wu B; Li A; Zhang Y; Liu X; Zhou S; Gan H; Cai S; Liang Y; Tang X
Expert Opin Drug Deliv; 2020 Apr; 17(4):573-587. PubMed ID: 32056461
[No Abstract] [Full Text] [Related]
10. A novel all-trans retinoic acid derivative 4-amino‑2‑trifluoromethyl-phenyl retinate inhibits the proliferation of human hepatocellular carcinoma HepG2 cells by inducing G0/G1 cell cycle arrest and apoptosis via upregulation of p53 and ASPP1 and downregulation of iASPP.
Liu H; Chen F; Zhang L; Zhou Q; Gui S; Wang Y
Oncol Rep; 2016 Jul; 36(1):333-41. PubMed ID: 27177208
[TBL] [Abstract][Full Text] [Related]
11. Active Targeting of Sorafenib: Preparation, Characterization, and In Vitro Testing of Drug-Loaded Magnetic Solid Lipid Nanoparticles.
Grillone A; Riva ER; Mondini A; Forte C; Calucci L; Innocenti C; de Julian Fernandez C; Cappello V; Gemmi M; Moscato S; Ronca F; Sacco R; Mattoli V; Ciofani G
Adv Healthc Mater; 2015 Aug; 4(11):1681-90. PubMed ID: 26039933
[TBL] [Abstract][Full Text] [Related]
12. Modulating the site-specific oral delivery of sorafenib using sugar-grafted nanoparticles for hepatocellular carcinoma treatment.
Tunki L; Kulhari H; Vadithe LN; Kuncha M; Bhargava S; Pooja D; Sistla R
Eur J Pharm Sci; 2019 Sep; 137():104978. PubMed ID: 31254645
[TBL] [Abstract][Full Text] [Related]
13. Antihepatoma peptide, scolopentide, derived from the centipede scolopendra subspinipes mutilans.
Hu YX; Liu Z; Zhang Z; Deng Z; Huang Z; Feng T; Zhou QH; Mei S; Yi C; Zhou Q; Zeng PH; Pei G; Tian S; Tian XF
World J Gastroenterol; 2023 Mar; 29(12):1875-1898. PubMed ID: 37032730
[TBL] [Abstract][Full Text] [Related]
14. Targeted Therapy for Hepatocellular Carcinoma: Co-Delivery of Sorafenib and Curcumin Using Lactosylated pH-Responsive Nanoparticles.
Bian Y; Guo D
Drug Des Devel Ther; 2020; 14():647-659. PubMed ID: 32109990
[TBL] [Abstract][Full Text] [Related]
15. Cucurbitacin E shows synergistic effect with sorafenib by inducing apoptosis in hepatocellular carcinoma cells and regulates Jak/Stat3, ERK/MAPK, PI3K/Akt/mTOR signaling pathways.
Üremiş MM; Üremiş N; Türköz Y
Steroids; 2023 Oct; 198():109261. PubMed ID: 37355001
[TBL] [Abstract][Full Text] [Related]
16. Comparative Analysis of the Cytotoxic Effect of a Complex of Selenium Nanoparticles Doped with Sorafenib, "Naked" Selenium Nanoparticles, and Sorafenib on Human Hepatocyte Carcinoma HepG2 Cells.
Varlamova EG; Goltyaev MV; Simakin AV; Gudkov SV; Turovsky EA
Int J Mol Sci; 2022 Jun; 23(12):. PubMed ID: 35743086
[TBL] [Abstract][Full Text] [Related]
17. SPARC regulates ferroptosis induced by sorafenib in human hepatocellular carcinoma.
Hua HW; Jiang HS; Jia L; Jia YP; Yao YL; Chen YW; Jiang F; Lu DQ; Zhou Q; Jiang MW; Ding G
Cancer Biomark; 2021; 32(4):425-433. PubMed ID: 33843664
[TBL] [Abstract][Full Text] [Related]
18. Sorafenib and CuB exert synergistic antitumor effects against hepatocellular carcinoma cells via inhibition of STAT3 phosphorylation.
Wang X; Li H; Li D; Bai Y; Zhang Y; Yan X; Li J; Zhao R; Liu J; Liu W; Shi M; Xu C; Yang T; Zhang T
FEBS Open Bio; 2021 Jan; 11(1):133-145. PubMed ID: 33176070
[TBL] [Abstract][Full Text] [Related]
19. Targeted therapy for human hepatic carcinoma cells using folate-functionalized polymeric micelles loaded with superparamagnetic iron oxide and sorafenib in vitro.
Zhang L; Gong F; Zhang F; Ma J; Zhang P; Shen J
Int J Nanomedicine; 2013; 8():1517-24. PubMed ID: 23620667
[TBL] [Abstract][Full Text] [Related]
20. Current status of sorafenib nanoparticle delivery systems in the treatment of hepatocellular carcinoma.
Kong FH; Ye QF; Miao XY; Liu X; Huang SQ; Xiong L; Wen Y; Zhang ZJ
Theranostics; 2021; 11(11):5464-5490. PubMed ID: 33859758
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]